A validated LC method for the determination of clopidogrel in pharmaceutical preparations

被引:62
作者
Mitakos, A [1 ]
Panderi, I [1 ]
机构
[1] Univ Athens, Sch Pharm, Div Pharmaceut Chem, GR-15771 Athens, Greece
关键词
clopidogrel; liquid chromatography; pharmaceutical dosage forms; stability indicating;
D O I
10.1016/S0731-7085(01)00620-3
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A stability indicating, reversed-phase high-performance liquid chromatographic method was developed and validated for the determination of clopidogrel in pharmaceutical dosage forms. The determination was performed on a semi-micro column, BDS C8 (250 x 2.1 mm i.d., 5 mum particle size); the mobile phase consisted of a mixture of 0.010 M sodium dihydrogen phosphate (pH 3.0) and acetonitrile (35:65, v/v), pumped at a flow rate 0.30 ml min(-1). The UV detector was operated at 235 nm. The retention times for clopidogrel and naproxen, which was used as internal standard, were 3.08 and 6.28 min, respectively. Calibration graphs are linear (r better than 0.9991, n = 6), in concentration range 1.00-3.00 mug ml(-1) for clopidogrel. The intra- and inter-day RSD values were less than 1.96%, while the relative percentage error E, was less than 2.0% (n = 5). Detection and quantitation limits were 0.12 and 0.39 mug ml(-1), respectively. The method was applied in the quality control of commercial tablets and content uniformity test and proved to be suitable for rapid and reliable quality control. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:431 / 438
页数:8
相关论文
共 21 条
[1]  
[Anonymous], 1995, US PHARMACOPEIAL CON
[2]  
CAMPANA AMG, 1998, BIOMED CHROMATOGR, V12, P177
[3]  
Caplain H, 1999, SEMIN THROMB HEMOST, V25, P25
[4]   Simultaneous determination of benzodiazepines in whole blood or serum by HPLC/DAD with a semi-micro column [J].
El Mahjoub, A ;
Staub, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 23 (2-3) :447-458
[5]  
Gardell S. J., 1993, PERSPECT DRUG DISCOV, V1, P521
[6]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[7]   CLOPIDOGREL, A NOVEL ANTIPLATELET AND ANTITHROMBOTIC AGENT [J].
HERBERT, JM ;
FREHEL, D ;
VALLEE, E ;
KIEFFER, G ;
GOUY, D ;
BERGER, Y ;
NECCIARI, J ;
DEFREYN, G ;
MAFFRAND, JP .
CARDIOVASCULAR DRUG REVIEWS, 1993, 11 (02) :180-198
[8]   Chromatographic method validation: A review of current practices and procedures .3. Ruggedness, revalidation and system suitability [J].
Jenke, DR .
JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 1996, 19 (12) :1873-1891
[9]   Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography mass spectrometry [J].
Lagorce, P ;
Perez, Y ;
Ortiz, J ;
Necciari, J ;
Bressolle, F .
JOURNAL OF CHROMATOGRAPHY B, 1998, 720 (1-2) :107-117
[10]   LIMIT OF DETECTION [J].
LONG, GL ;
WINEFORDNER, JD .
ANALYTICAL CHEMISTRY, 1983, 55 (07) :A712-+